NCRI Clinical Trials Unit

NCRI Clinical Trials Unit
Name	NCRI Clinical Trials Unit

NCRI Clinical Trials Unit The NCRI Clinical Trials Unit is a UK-based clinical trials coordinating center associated with national cancer research networks and academic institutions. It conducts, designs, and manages multicenter randomized controlled trials and translational studies in oncology, working with hospitals, universities, and regulatory agencies to deliver evidence that informs practice and policy.

Overview

The unit operates within a landscape that includes National Institute for Health and Care Research, Medical Research Council, Cancer Research UK, Wellcome Trust, European Commission, World Health Organization, National Health Service, University of Oxford, University College London, University of Cambridge, Imperial College London, King's College London, University of Manchester, University of Edinburgh, University of Glasgow, University of Birmingham, University of Leeds, University of Southampton, University of Bristol, Queen Mary University of London, University of Nottingham, University of Sheffield, Newcastle University, University of Liverpool, Cardiff University, University of Leicester, University of Dundee, University of Aberdeen, London School of Hygiene & Tropical Medicine, Royal Marsden Hospital, Christie Hospital, Clatterbridge Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, Addenbrooke's Hospital, Barts Health NHS Trust, Oxford University Hospitals NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust and Royal Free London through networks and clinical sites.

History and Development

The unit's origins trace through initiatives funded by Department of Health and Social Care, collaborations with European Organisation for Research and Treatment of Cancer, and methodological advances influenced by trials run at MRC Clinical Trials Unit at UCL, Cancer Research UK Clinical Trials Unit, NHSBT, National Cancer Institute (USA), European Medicines Agency, Food and Drug Administration, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Council of Europe, Academy of Medical Sciences, Royal Society, Royal College of Physicians, Royal College of Surgeons, and historical trials such as those at Royal Marsden Hospital and Christie Hospital. Key phases involved alignment with frameworks from Clinical Trials Transformation Initiative, adoption of guidance from International Conference on Harmonisation, and partnerships tied to consortia like European Union's Horizon 2020 and Innovate UK.

Research Areas and Trial Portfolio

The unit designs trials spanning oncology specialties including breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, pancreatic cancer, glioblastoma, melanoma, haematological malignancy, lymphoma, leukaemia, myeloma, sarcoma, head and neck cancer, gynaecological oncology, urological oncology, paediatric oncology, and trials involving radiotherapy, chemotherapy, immunotherapy, targeted therapy, precision medicine, biomarkers, and companion diagnostics. Portfolio elements reference study designs influenced by James Lind Alliance, CONSORT Statement, SPIRIT Statement, STROBE Statement, RECORD Statement, PROSPERO, Cochrane Collaboration, European Society for Medical Oncology, American Society of Clinical Oncology, International Society for Clinical Trials, and trial endpoints considered by RECIST and Common Terminology Criteria for Adverse Events frameworks.

Governance and Funding

Governance structures align with oversight from Health Research Authority, Medicines and Healthcare products Regulatory Agency, Research Ethics Committee, Data Monitoring Committee, and institutional boards at partner universities including University of Oxford and University College London. Funders and sponsors in the portfolio include Cancer Research UK, Medical Research Council, National Institute for Health and Care Research, Wellcome Trust, European Commission, Pharmaceutical Research and Manufacturers of America, Innovate UK, Economic and Social Research Council, and charitable partners such as Macmillan Cancer Support, Vera Baird Foundation, and disease-specific charities.

Methodology and Trial Infrastructure

Methodological work draws on statistical methods from groups at MRC Biostatistics Unit (Cambridge), London School of Hygiene & Tropical Medicine, Nuffield Department of Population Health, Institute of Cancer Research, CRUK Manchester Institute, and incorporates data standards promoted by Health Level Seven International, CDISC, Clinical Data Interchange Standards Consortium, Good Clinical Practice (GCP), ICH-GCP, and data protection aligned with Information Commissioner's Office. Infrastructure includes electronic data capture systems used in trials at NHS Digital, imaging core labs like those affiliated with European Society of Radiology, central laboratories tied to UK Biobank, sample handling coordinated with Biobank UK, and trial management systems interoperable with OpenClinica and platforms from Medidata Solutions.

Collaborations and Partnerships

The unit collaborates with academic hubs including University of Oxford, University College London, Imperial College London, University of Cambridge, University of Manchester, clinical centers such as Royal Marsden Hospital, Christie Hospital, Clatterbridge Cancer Centre, regulatory agencies like Medicines and Healthcare products Regulatory Agency, funders like Cancer Research UK, international partners including European Organisation for Research and Treatment of Cancer, National Cancer Institute (USA), European Society for Medical Oncology, and industry sponsors ranging from multinational pharmaceutical firms to biotech companies incubated at Oxford BioMedica and Cambridge Biomedical Campus institutions.

Impact and Notable Trials

The unit's trials have influenced practice guidelines from bodies such as National Institute for Health and Care Excellence, European Society for Medical Oncology, and American Society of Clinical Oncology by contributing evidence on systemic therapies, surgery, and radiotherapy modalities evaluated alongside work from MRC Clinical Trials Unit at UCL, Trials Unit at University of Birmingham, Cancer Research UK Clinical Trials Unit, and international consortia like EORTC. Notable trial findings have been discussed at conferences including ASCO Annual Meeting, ESMO Congress, European Cancer Congress, European Society for Radiotherapy and Oncology, San Antonio Breast Cancer Symposium, and published alongside cohorts from UK Biobank and datasets cross-referenced with registries like National Cancer Registration and Analysis Service.

Category:Clinical trials units